What is the recommended treatment regimen for an adult with stable chronic obstructive pulmonary disease, including drug choices and dosing?

Treatment of Stable COPD: Drug Regimens and Dosing

For stable COPD, initiate treatment with a long-acting bronchodilator (LAMA or LABA) for symptomatic patients, escalate to LAMA/LABA dual therapy for persistent symptoms or high exacerbation risk, and reserve triple therapy (LAMA/LABA/ICS) for patients with continued exacerbations despite dual bronchodilators, particularly when blood eosinophils ≥300 cells/μL. 1

Initial Pharmacologic Approach

Low Symptom Burden, Low Exacerbation Risk

• Start with short-acting bronchodilators as needed (albuterol 90 mcg, 2 puffs every 4-6 hours PRN)
• If symptoms persist, advance to a single long-acting bronchodilator

Moderate-High Symptom Burden, Low Exacerbation Risk

• Begin with a single long-acting bronchodilator:
  • LAMA (preferred): Tiotropium 18 mcg once daily OR Umeclidinium 62.5 mcg once daily
  • LABA: Formoterol 12 mcg twice daily OR Salmeterol 50 mcg twice daily
• If breathlessness persists on monotherapy, escalate to LAMA/LABA combination 2:
  • Umeclidinium/vilanterol 62.5/25 mcg once daily
  • Tiotropium/olodaterol 5/5 mcg once daily
  • Glycopyrrolate/formoterol 18/9.6 mcg twice daily

High Exacerbation Risk (≥2 moderate or ≥1 severe exacerbation/year)

Start with LAMA/LABA dual bronchodilator therapy (dosing as above) 2. This is superior to LABA/ICS for exacerbation prevention and avoids pneumonia risk associated with ICS.

Alternative for specific phenotypes: LABA/ICS may be first-line if:

• Features suggesting asthma-COPD overlap
• Blood eosinophils ≥300 cells/μL 1
• Example: Fluticasone/salmeterol 250/50 mcg twice daily OR Budesonide/formoterol 160/4.5 mcg twice daily

Escalation for Persistent Exacerbations

Triple Therapy (LAMA/LABA/ICS)

If exacerbations continue on LAMA/LABA, escalate to triple therapy 1:

• Budesonide/glycopyrrolate/formoterol:

  • 160/18/9.6 mcg twice daily (preferred for most patients)
  • 320/18/9.6 mcg twice daily (no additional exacerbation benefit, but mortality benefit demonstrated in ETHOS trial) 1

• Fluticasone furoate/umeclidinium/vilanterol: 100/62.5/25 mcg once daily

• Beclomethasone/glycopyrrolate/formoterol: 87/9/5 mcg twice daily

Critical point: High-dose ICS is not necessary for exacerbation reduction—moderate doses are sufficient and reduce adverse effects. The ETHOS trial showed no difference in exacerbation rates between 160 mg and 320 mg budesonide, though moderate dose showed mortality benefit 1.

Pneumonia risk: Number needed to harm is 33 patients for 1 year to cause one pneumonia, versus number needed to treat of 4 patients to prevent one exacerbation 1. This favorable risk-benefit ratio supports triple therapy use despite pneumonia concerns.

Add-On Therapies for Refractory Disease

If exacerbations persist despite triple therapy:

Macrolide Maintenance (Preferred Add-On)

Azithromycin 250 mg daily or 500 mg three times weekly 1

Prerequisites before initiating:

• Former smoker (not current smoker)
• Normal QT interval on ECG
• No drug interactions with concomitant medications
• Rule out atypical mycobacterial infection (sputum culture)

Roflumilast

500 mcg once daily for patients with 1, 2:

• FEV₁ <50% predicted
• Chronic bronchitis phenotype
• History of hospitalization for exacerbation in previous year

N-Acetylcysteine

600 mg twice daily for chronic bronchitic phenotype 1

What NOT to Use

Avoid these therapies for stable COPD maintenance:

• Systemic oral corticosteroids (prednisone) for maintenance—no role despite older studies showing short-term benefit 1, 3
• ICS monotherapy—always combine with long-acting bronchodilators 1
• Theophylline—narrow therapeutic window, significant drug interactions 1

Key Dosing Principles

• Single-inhaler triple therapy is preferred over multiple-inhaler regimens when triple therapy is indicated 1
• Do not step down from triple therapy in high-risk patients—ICS withdrawal increases exacerbation risk, especially with eosinophils ≥300 cells/μL 1
• Blood eosinophil counts guide ICS decisions: ≥300 cells/μL predicts better ICS response; <100 cells/μL suggests minimal ICS benefit 4, 5

Common Pitfalls

• Starting with triple therapy in low-risk patients—this unnecessarily exposes patients to pneumonia risk
• Using high-dose ICS when moderate doses suffice
• Continuing ICS in patients with recurrent pneumonia and low eosinophils
• Forgetting to screen for mycobacterial infection before starting macrolides
• Prescribing maintenance oral corticosteroids—this causes more harm than benefit long-term